Stephen K. Doberstein Ph.D. — Senior VP of Research & Development and Chief Research & Development Officer at Nektar Therapeutics

Dr. Stephen K. Doberstein, also known as Steve, Ph.D., has been Senior VP of Research & Development and Chief Research & Development Officer at Nektar Therapeutics since November 22, 2017. Dr. Doberstein served as Chief Scientific Officer and Senior Vice President of Nektar Therapeutics from January 06, 2010 to November 22, 2017. Dr. Doberstein served as Vice President of Research of XOMA Corporation since October 28, 2008, where he was responsible for directing the discovery and development of their drug candidates, including antibody discovery and support of clinical development through non-clinical safety, translational medicine and pharmacokinetics/ pharmacodynamics. He has 17 years of experience in biotechnology research and development. Most recently, he served as Vice President of Research at Five Prime Therapeutics, Inc., since July 2004. While at Five Prime, he established programs resulting in multiple strategic alliances with pharmaceutical partners, built a strong proprietary pipeline and moved multiple product candidates from concept to pre-IND stages in diabetes, oncology, rheumatoid arthritis and osteoarthritis. He served as Vice President of Research at Xencor, Inc., where he was instrumental in advancing its protein platform technologies and preclinical product candidates. Dr. Doberstein held a variety of positions at Explicit, including Director of Pharmaceutical Target Research and Director, Cell Biology. He was employed at Exelixis, Inc. He began his career as an Engineer at DuPont. He has been a Member of Scientific Advisory Board at Phylogica Limited since October 2017. He holds a Ph.D. in Biochemistry, Cell and Molecular Biology from Johns Hopkins University School of Medicine and completed his postdoctoral work at UC Berkeley. Dr. Doberstein earned his B.S.Ch.E. degree in Chemical Engineering from the University of Delaware.